ERBB2 and breast carcinoma: We performed a retrospective/prospective review of medical records of women with HR-positive/HER2-negative advanced breast cancer, who received treatment with endocrine therapy combined with CDKi, at Departments of Oncology that are affiliated to the Hellenic Cooperative Oncology Group (HeCOG).